Evidence map›Paper›PMID 28008281›Full record

ArticleJournal of pain research2016

Nicoboxil/nonivamide cream effectively and safely reduces acute nonspecific low back pain - a randomized, placebo-controlled trial.

Zuzana Blahova, Janina Claudia Holm, Thomas Weiser, Erika Richter, Matthias Trampisch, Elena Akarachkova

Open access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Zuzana BlahovaBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Janina Claudia HolmBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Thomas WeiserBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
Erika RichterBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
Matthias TrampischBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
Elena AkarachkovaI.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (Austria) · ATSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectiveLow back pain affects many patients and has a high socioeconomic impact. Topical capsaicinoids have been used for decades to treat musculoskeletal pain. This study investigated the effects of the fixed dose combination (FDC) of nonivamide (a capsaicinoid) and nicoboxil (a nicotinic acid ester) cream in the treatment of acute nonspecific low back pain. MATERIALS AND

methodsThis phase III randomized, double-blind, placebo-controlled, multinational, multi-center trial investigated efficacy, safety, and tolerability of topical nicoboxil 1.08%/nonivamide 0.17% (Finalgon

resultsPatients (n=138), 21-65 years of age, were treated for up to 4 days with FDC or placebo cream. Mean baseline PI was 6.8 on a 0-10 point numerical rating scale. After 8 hours, pain was more reduced with the FDC than with placebo (adjusted means: 2.824 vs. 0.975 points;

conclusionNicoboxil/nonivamide cream is an effective and safe treatment for acute nonspecific low back pain, adding a promising treatment option.

Indexed as

efficacyFinalgon®mobility scorepain reduction

Identifiers

PMID28008281
PMCPMC5167490
OpenAlexW2563035104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.